FindTrial
Sign In

ALT-801

BIOLOGICAL11 trials

Sponsors

Altor BioScience, Altimmune, Inc.

Conditions

Acute Myeloid LeukemiaMalignant Tumor of Renal PelvisMetastatic MelanomaNon-Alcoholic Fatty Liver DiseaseNon-muscle Invasive Bladder CancerNonalcoholic SteatohepatitisObesityObesity/Overweight

Phase 1

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
CompletedNCT00496860
Altor BioScienceProgressive Metastatic Malignancies
Start: 2007-05-31End: 2009-10-31Updated: 2013-07-22
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma
TerminatedNCT01029873
Altor BioScienceMetastatic Melanoma
Start: 2010-02-01End: 2013-09-01Updated: 2026-09-10
A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer
CompletedNCT01326871
Altor BioScienceMalignant Tumor of Renal Pelvis, Transitional Cell Carcinoma of Bladder, Ureter Cancer +1
Start: 2011-09-06End: 2016-04-11Updated: 2024-06-25
ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia
WithdrawnNCT01478074
Altor BioScienceAcute Myeloid Leukemia
Start: 2011-11-30End: 2013-11-30Updated: 2014-01-03
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
TerminatedNCT01625260
Altor BioScienceNon-muscle Invasive Bladder Cancer
Start: 2012-03-30End: 2018-03-08Updated: 2024-07-19
QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma
TerminatedNCT01670994
Altor BioScienceRelapsed or Refractory Multiple Myeloma
Start: 2012-08-14End: 2015-09-09Updated: 2024-06-18
ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
CompletedNCT04561245
Altimmune, Inc.Nonalcoholic Steatohepatitis, Obesity
Start: 2020-11-10End: 2021-10-29Updated: 2025-06-24
ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)
CompletedNCT05006885
Altimmune, Inc.Non-Alcoholic Fatty Liver Disease
Start: 2021-09-30End: 2022-08-17Updated: 2023-07-27
ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)
CompletedNCT05134662
Altimmune, Inc.Type 2 Diabetes
Start: 2022-02-01End: 2023-03-09Updated: 2025-06-24
Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)
CompletedNCT05292911
Altimmune, Inc.Non-Alcoholic Fatty Liver Disease
Start: 2022-03-09End: 2022-10-31Updated: 2023-07-27

Phase 2

Efficacy and Safety of ALT-801 in the Treatment of Obesity
CompletedNCT05295875
Altimmune, Inc.Obesity/Overweight
Start: 2022-03-31End: 2023-09-28Updated: 2023-11-29

Related Papers

Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.
2025-06-18
Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study
Journal of Hepatology2024-07-11102 citations
Phase I trial of ALT-801, a first-in-class T-cell receptor (TCR)-interleukin (IL)-2 fusion molecule, plus gemcitabine (G) for Bacillus Calmette Guerin (BCG)-resistant non-muscle-invasive bladder cancer (NMIBC).
Journal of Clinical Oncology2016-01-1015 citations
Phase I trial of ALT-801, a first-in-class T-cell receptor (TCR)-interleukin (IL)-2 fusion molecule, plus gemcitabine (G) for Bacillus Calmette Guerin (BCG)-resistant non-muscle-invasive bladder cancer (NMIBC).
Journal of Clinical Oncology2015-05-2011 citations
Phase Ib/II study of an IL-2/T-cell receptor fusion protein in combination with gemcitabine and cisplatin in advanced or metastatic chemo-refractory urothelial cancer (UC).
Journal of Clinical Oncology2015-05-207 citations